CanSino Biologics Price To Book vs. Current Valuation

CJH Stock   4.08  0.12  3.03%   
Based on CanSino Biologics' profitability indicators, CanSino Biologics may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess CanSino Biologics' ability to earn profits and add value for shareholders.
For CanSino Biologics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of CanSino Biologics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well CanSino Biologics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between CanSino Biologics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of CanSino Biologics over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Please note, there is a significant difference between CanSino Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CanSino Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CanSino Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

CanSino Biologics Current Valuation vs. Price To Book Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining CanSino Biologics's current stock value. Our valuation model uses many indicators to compare CanSino Biologics value to that of its competitors to determine the firm's financial worth.
CanSino Biologics is rated below average in price to book category among its peers. It also is rated below average in current valuation category among its peers reporting about  1,510,989,842  of Current Valuation per Price To Book. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the CanSino Biologics' earnings, one of the primary drivers of an investment's value.

CanSino Current Valuation vs. Price To Book

Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

CanSino Biologics

P/B

 = 

MV Per Share

BV Per Share

 = 
2.25 X
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

CanSino Biologics

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
3.4 B
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.

CanSino Current Valuation vs Competition

CanSino Biologics is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Drug Manufacturers-Specialty & Generic industry is currently estimated at about 62.44 Billion. CanSino Biologics holds roughly 3.4 Billion in current valuation claiming about 5% of equities under Drug Manufacturers-Specialty & Generic industry.

CanSino Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on CanSino Biologics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of CanSino Biologics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the CanSino Biologics' important profitability drivers and their relationship over time.

Use CanSino Biologics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CanSino Biologics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CanSino Biologics will appreciate offsetting losses from the drop in the long position's value.

CanSino Biologics Pair Trading

CanSino Biologics Pair Trading Analysis

The ability to find closely correlated positions to CanSino Biologics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CanSino Biologics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CanSino Biologics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CanSino Biologics to buy it.
The correlation of CanSino Biologics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CanSino Biologics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CanSino Biologics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CanSino Biologics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your CanSino Biologics position

In addition to having CanSino Biologics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run High Dividend Yield ETFs Thematic Idea Now

High Dividend Yield ETFs
High Dividend Yield ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The High Dividend Yield ETFs theme has 107 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize High Dividend Yield ETFs Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for CanSino Stock Analysis

When running CanSino Biologics' price analysis, check to measure CanSino Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CanSino Biologics is operating at the current time. Most of CanSino Biologics' value examination focuses on studying past and present price action to predict the probability of CanSino Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CanSino Biologics' price. Additionally, you may evaluate how the addition of CanSino Biologics to your portfolios can decrease your overall portfolio volatility.